ACHE and Alzheimer disease: In fact, recently reported conjugates of BIM derivatives with two anti-AD approved drugs, namely, tacrine and donepezil pharmacophores, were proven to endow the corresponding molecular hybrids with improved AChE inhibitory capacity and other relevant biological activities in the context of well-recognized targets for AD therapy [35,44].